Anil Gulati, MD, PhD, is Professor Emeritus at Midwestern University, the University of Illinois at Chicago, and is a consultant to Advocate Lutheran General Children's Hospital. He is Chairman and Chief Executive Officer at Pharmazz, Inc., Willowbrook, Illinois. Dr. Gulati is leading the clinical development and commercialization of first-in-class drug products in critical care medicine. He has led the research, and invented, developed, and obtained marketing authorization for a first-in-class resuscitative agent indicated for patients with hypovolemic shock as a frontline adjuvant to the standard of care. His main focus is the discovery of drugs to treat cerebral stroke and Alzheimer's disease, and resuscitative agents for shock. He has 54 issued patents. He is a recipient of the Outstanding Faculty Award 2017, the Paul R Dawson Biotechnology Award 2014, and the distinguished Littlejohn Award 2014. Dr. Gulati is not only a United States Fulbright Scholar 2008-2009, but he is also a winner of the International Ranbaxy Research Award 2007. Dr. Gulati was the Scientific Reviewer of the United States Defense Medical Research and Development Program, Combat Casualty Care Research Program 2016 and 2017.